Review



human bcma tnfsrf17 protein fc tag  (ACROBiosystems)


Bioz Verified Symbol ACROBiosystems is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    ACROBiosystems human bcma tnfsrf17 protein fc tag
    Human Bcma Tnfsrf17 Protein Fc Tag, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 31 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcma/pmc10657357-229-9-22?v=ACROBiosystems
    Average 95 stars, based on 31 article reviews
    human bcma tnfsrf17 protein fc tag - by Bioz Stars, 2026-07
    95/100 stars

    Images



    Similar Products

    bcma  (Miltenyi Biotec)
    93
    Miltenyi Biotec bcma
    Gating strategy for the single-step method. Absolute counting beads were excluded based on scatter and fluorescence properties. Dead cells were excluded using 7-aminoactinomycin D (7-AAD). CD45-positive leukocytes were selected, and lymphocytes were identified according to side scatter (SSC) characteristics. CD3-positive T cells were gated, <t>and</t> <t>CAR-T</t> cells were defined as viable CD45+/CD3+/CAR+ events using directly fluorochrome-conjugated CAR detection reagents (CD19 or <t>BCMA).</t> CD4 and CD8 subpopulations were subsequently identified within the CAR-positive T-cell compartment. Absolute quantification was calculated using TruCount beads according to the manufacturer’s formula.
    Bcma, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcma/pmc13106092-71-10-13?v=Miltenyi+Biotec
    Average 93 stars, based on 1 article reviews
    bcma - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    elisa  (R&D Systems)
    94
    R&D Systems elisa
    Gating strategy for the single-step method. Absolute counting beads were excluded based on scatter and fluorescence properties. Dead cells were excluded using 7-aminoactinomycin D (7-AAD). CD45-positive leukocytes were selected, and lymphocytes were identified according to side scatter (SSC) characteristics. CD3-positive T cells were gated, <t>and</t> <t>CAR-T</t> cells were defined as viable CD45+/CD3+/CAR+ events using directly fluorochrome-conjugated CAR detection reagents (CD19 or <t>BCMA).</t> CD4 and CD8 subpopulations were subsequently identified within the CAR-positive T-cell compartment. Absolute quantification was calculated using TruCount beads according to the manufacturer’s formula.
    Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcma/pm42010117-257-20-26?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    elisa - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    human bcma tnfrsf17 duoset elisa kit  (R&D Systems)
    94
    R&D Systems human bcma tnfrsf17 duoset elisa kit
    Gating strategy for the single-step method. Absolute counting beads were excluded based on scatter and fluorescence properties. Dead cells were excluded using 7-aminoactinomycin D (7-AAD). CD45-positive leukocytes were selected, and lymphocytes were identified according to side scatter (SSC) characteristics. CD3-positive T cells were gated, <t>and</t> <t>CAR-T</t> cells were defined as viable CD45+/CD3+/CAR+ events using directly fluorochrome-conjugated CAR detection reagents (CD19 or <t>BCMA).</t> CD4 and CD8 subpopulations were subsequently identified within the CAR-positive T-cell compartment. Absolute quantification was calculated using TruCount beads according to the manufacturer’s formula.
    Human Bcma Tnfrsf17 Duoset Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcma/pm41976339-86-12-18?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    human bcma tnfrsf17 duoset elisa kit - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    elisa analysis  (R&D Systems)
    94
    R&D Systems elisa analysis
    Gating strategy for the single-step method. Absolute counting beads were excluded based on scatter and fluorescence properties. Dead cells were excluded using 7-aminoactinomycin D (7-AAD). CD45-positive leukocytes were selected, and lymphocytes were identified according to side scatter (SSC) characteristics. CD3-positive T cells were gated, <t>and</t> <t>CAR-T</t> cells were defined as viable CD45+/CD3+/CAR+ events using directly fluorochrome-conjugated CAR detection reagents (CD19 or <t>BCMA).</t> CD4 and CD8 subpopulations were subsequently identified within the CAR-positive T-cell compartment. Absolute quantification was calculated using TruCount beads according to the manufacturer’s formula.
    Elisa Analysis, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcma/pm41976339-86-8-18?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    elisa analysis - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    bispecific bcma directed cd3 t cell engager  (Janssen)
    86
    Janssen bispecific bcma directed cd3 t cell engager
    Gating strategy for the single-step method. Absolute counting beads were excluded based on scatter and fluorescence properties. Dead cells were excluded using 7-aminoactinomycin D (7-AAD). CD45-positive leukocytes were selected, and lymphocytes were identified according to side scatter (SSC) characteristics. CD3-positive T cells were gated, <t>and</t> <t>CAR-T</t> cells were defined as viable CD45+/CD3+/CAR+ events using directly fluorochrome-conjugated CAR detection reagents (CD19 or <t>BCMA).</t> CD4 and CD8 subpopulations were subsequently identified within the CAR-positive T-cell compartment. Absolute quantification was calculated using TruCount beads according to the manufacturer’s formula.
    Bispecific Bcma Directed Cd3 T Cell Engager, supplied by Janssen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcma/pmc13065502-15-11-6?v=Janssen
    Average 86 stars, based on 1 article reviews
    bispecific bcma directed cd3 t cell engager - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    recombinant bcma protein  (ACROBiosystems)
    95
    ACROBiosystems recombinant bcma protein
    (a) Timeline of T cell knock-in electroporation workflow, knock-in strategy and designs for <t>BCMA-CAR</t> (1.6 kb integration) across the series of DNA HDR template formats tested. (b) Comparison of BCMA-CAR HDRTs at concentrations 5nM-160nM or 0-100E3 MOI in terms of knock-in efficiency, (c) live cell count per 1e6 edited cells, and (d) knock-in cell count per 1e6 edited cells measured 7 days post electroporation. (e) Knock-in of a logic-gated synNotch circuit (5.6 kb integration) using linear ssDNA + tCTS, circular cssDNA + CTS, and nanoplasmid + CTS templates with corresponding knock-in efficiency, live cell count and knock-in cell count 7 days post electroporation using Cas9 mRNA. Circular cssDNA was produced and provided by Kano Therapeutics. (f) Knock-in strategy and designs for a logic-gated synNotch circuit (5.6 kb integration) at concentrations 5nM-160nM with corresponding knock-in efficiency, live cell count, and knock-in cell count 7 days post electroporation using Cas9 RNP or Cas9 mRNA. Each experiment was performed with T cells from two independent healthy human blood donors represented by individual dots plus mean. CTS, Cas9 target site. RNP, ribonucleoprotein. MOI, multiplicity of infection.
    Recombinant Bcma Protein, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcma/bio_rxiv__64898__2026__04__09__717505-230-23-34?v=ACROBiosystems
    Average 95 stars, based on 1 article reviews
    recombinant bcma protein - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier
    room temperature  (ACROBiosystems)
    95
    ACROBiosystems room temperature
    (a) Timeline of T cell knock-in electroporation workflow, knock-in strategy and designs for <t>BCMA-CAR</t> (1.6 kb integration) across the series of DNA HDR template formats tested. (b) Comparison of BCMA-CAR HDRTs at concentrations 5nM-160nM or 0-100E3 MOI in terms of knock-in efficiency, (c) live cell count per 1e6 edited cells, and (d) knock-in cell count per 1e6 edited cells measured 7 days post electroporation. (e) Knock-in of a logic-gated synNotch circuit (5.6 kb integration) using linear ssDNA + tCTS, circular cssDNA + CTS, and nanoplasmid + CTS templates with corresponding knock-in efficiency, live cell count and knock-in cell count 7 days post electroporation using Cas9 mRNA. Circular cssDNA was produced and provided by Kano Therapeutics. (f) Knock-in strategy and designs for a logic-gated synNotch circuit (5.6 kb integration) at concentrations 5nM-160nM with corresponding knock-in efficiency, live cell count, and knock-in cell count 7 days post electroporation using Cas9 RNP or Cas9 mRNA. Each experiment was performed with T cells from two independent healthy human blood donors represented by individual dots plus mean. CTS, Cas9 target site. RNP, ribonucleoprotein. MOI, multiplicity of infection.
    Room Temperature, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcma/bio_rxiv__64898__2026__04__09__717505-212-30-24?v=ACROBiosystems
    Average 95 stars, based on 1 article reviews
    room temperature - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier
    bcma recombinant protein conjugated to biotin  (ACROBiosystems)
    95
    ACROBiosystems bcma recombinant protein conjugated to biotin
    (a) Timeline of T cell knock-in electroporation workflow, knock-in strategy and designs for <t>BCMA-CAR</t> (1.6 kb integration) across the series of DNA HDR template formats tested. (b) Comparison of BCMA-CAR HDRTs at concentrations 5nM-160nM or 0-100E3 MOI in terms of knock-in efficiency, (c) live cell count per 1e6 edited cells, and (d) knock-in cell count per 1e6 edited cells measured 7 days post electroporation. (e) Knock-in of a logic-gated synNotch circuit (5.6 kb integration) using linear ssDNA + tCTS, circular cssDNA + CTS, and nanoplasmid + CTS templates with corresponding knock-in efficiency, live cell count and knock-in cell count 7 days post electroporation using Cas9 mRNA. Circular cssDNA was produced and provided by Kano Therapeutics. (f) Knock-in strategy and designs for a logic-gated synNotch circuit (5.6 kb integration) at concentrations 5nM-160nM with corresponding knock-in efficiency, live cell count, and knock-in cell count 7 days post electroporation using Cas9 RNP or Cas9 mRNA. Each experiment was performed with T cells from two independent healthy human blood donors represented by individual dots plus mean. CTS, Cas9 target site. RNP, ribonucleoprotein. MOI, multiplicity of infection.
    Bcma Recombinant Protein Conjugated To Biotin, supplied by ACROBiosystems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcma/bio_rxiv__64898__2026__04__09__717505-212-10-24?v=ACROBiosystems
    Average 95 stars, based on 1 article reviews
    bcma recombinant protein conjugated to biotin - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier
    106 bcma cd 38 molp  (DSMZ)
    95
    DSMZ 106 bcma cd 38 molp
    (a) Timeline of T cell knock-in electroporation workflow, knock-in strategy and designs for <t>BCMA-CAR</t> (1.6 kb integration) across the series of DNA HDR template formats tested. (b) Comparison of BCMA-CAR HDRTs at concentrations 5nM-160nM or 0-100E3 MOI in terms of knock-in efficiency, (c) live cell count per 1e6 edited cells, and (d) knock-in cell count per 1e6 edited cells measured 7 days post electroporation. (e) Knock-in of a logic-gated synNotch circuit (5.6 kb integration) using linear ssDNA + tCTS, circular cssDNA + CTS, and nanoplasmid + CTS templates with corresponding knock-in efficiency, live cell count and knock-in cell count 7 days post electroporation using Cas9 mRNA. Circular cssDNA was produced and provided by Kano Therapeutics. (f) Knock-in strategy and designs for a logic-gated synNotch circuit (5.6 kb integration) at concentrations 5nM-160nM with corresponding knock-in efficiency, live cell count, and knock-in cell count 7 days post electroporation using Cas9 RNP or Cas9 mRNA. Each experiment was performed with T cells from two independent healthy human blood donors represented by individual dots plus mean. CTS, Cas9 target site. RNP, ribonucleoprotein. MOI, multiplicity of infection.
    106 Bcma Cd 38 Molp, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bcma/us12590168-912-8-16?v=DSMZ
    Average 95 stars, based on 1 article reviews
    106 bcma cd 38 molp - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Gating strategy for the single-step method. Absolute counting beads were excluded based on scatter and fluorescence properties. Dead cells were excluded using 7-aminoactinomycin D (7-AAD). CD45-positive leukocytes were selected, and lymphocytes were identified according to side scatter (SSC) characteristics. CD3-positive T cells were gated, and CAR-T cells were defined as viable CD45+/CD3+/CAR+ events using directly fluorochrome-conjugated CAR detection reagents (CD19 or BCMA). CD4 and CD8 subpopulations were subsequently identified within the CAR-positive T-cell compartment. Absolute quantification was calculated using TruCount beads according to the manufacturer’s formula.

    Journal: Frontiers in Oncology

    Article Title: Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells

    doi: 10.3389/fonc.2026.1774431

    Figure Lengend Snippet: Gating strategy for the single-step method. Absolute counting beads were excluded based on scatter and fluorescence properties. Dead cells were excluded using 7-aminoactinomycin D (7-AAD). CD45-positive leukocytes were selected, and lymphocytes were identified according to side scatter (SSC) characteristics. CD3-positive T cells were gated, and CAR-T cells were defined as viable CD45+/CD3+/CAR+ events using directly fluorochrome-conjugated CAR detection reagents (CD19 or BCMA). CD4 and CD8 subpopulations were subsequently identified within the CAR-positive T-cell compartment. Absolute quantification was calculated using TruCount beads according to the manufacturer’s formula.

    Article Snippet: New CAR detection reagent (CDR) directly coupled to fluorochrome, either BCMA (BCMA CDR-PE, Miltenyi Biotec 130-133-888) or CD19 (CD19 CDR α-FMC63-PE, Miltenyi Biotec 130-127-342) was added extemporaneously in the analytical tube.

    Techniques: Fluorescence, Quantitative Proteomics

    Determination of LOD and LLOQ for the single-step method. CAR-T cell absolute counts were measured in 10 negative control samples from patients not treated with CD19 or BCMA CAR-T cells. The blue line represents the mean background signal. LOD was defined as mean + 3 SD and LLOQ (green dashed line) as mean + 10 SD.

    Journal: Frontiers in Oncology

    Article Title: Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells

    doi: 10.3389/fonc.2026.1774431

    Figure Lengend Snippet: Determination of LOD and LLOQ for the single-step method. CAR-T cell absolute counts were measured in 10 negative control samples from patients not treated with CD19 or BCMA CAR-T cells. The blue line represents the mean background signal. LOD was defined as mean + 3 SD and LLOQ (green dashed line) as mean + 10 SD.

    Article Snippet: New CAR detection reagent (CDR) directly coupled to fluorochrome, either BCMA (BCMA CDR-PE, Miltenyi Biotec 130-133-888) or CD19 (CD19 CDR α-FMC63-PE, Miltenyi Biotec 130-127-342) was added extemporaneously in the analytical tube.

    Techniques: Negative Control

    (a) Timeline of T cell knock-in electroporation workflow, knock-in strategy and designs for BCMA-CAR (1.6 kb integration) across the series of DNA HDR template formats tested. (b) Comparison of BCMA-CAR HDRTs at concentrations 5nM-160nM or 0-100E3 MOI in terms of knock-in efficiency, (c) live cell count per 1e6 edited cells, and (d) knock-in cell count per 1e6 edited cells measured 7 days post electroporation. (e) Knock-in of a logic-gated synNotch circuit (5.6 kb integration) using linear ssDNA + tCTS, circular cssDNA + CTS, and nanoplasmid + CTS templates with corresponding knock-in efficiency, live cell count and knock-in cell count 7 days post electroporation using Cas9 mRNA. Circular cssDNA was produced and provided by Kano Therapeutics. (f) Knock-in strategy and designs for a logic-gated synNotch circuit (5.6 kb integration) at concentrations 5nM-160nM with corresponding knock-in efficiency, live cell count, and knock-in cell count 7 days post electroporation using Cas9 RNP or Cas9 mRNA. Each experiment was performed with T cells from two independent healthy human blood donors represented by individual dots plus mean. CTS, Cas9 target site. RNP, ribonucleoprotein. MOI, multiplicity of infection.

    Journal: bioRxiv

    Article Title: Ultra-large targeted DNA integrations in primary human cells

    doi: 10.64898/2026.04.09.717505

    Figure Lengend Snippet: (a) Timeline of T cell knock-in electroporation workflow, knock-in strategy and designs for BCMA-CAR (1.6 kb integration) across the series of DNA HDR template formats tested. (b) Comparison of BCMA-CAR HDRTs at concentrations 5nM-160nM or 0-100E3 MOI in terms of knock-in efficiency, (c) live cell count per 1e6 edited cells, and (d) knock-in cell count per 1e6 edited cells measured 7 days post electroporation. (e) Knock-in of a logic-gated synNotch circuit (5.6 kb integration) using linear ssDNA + tCTS, circular cssDNA + CTS, and nanoplasmid + CTS templates with corresponding knock-in efficiency, live cell count and knock-in cell count 7 days post electroporation using Cas9 mRNA. Circular cssDNA was produced and provided by Kano Therapeutics. (f) Knock-in strategy and designs for a logic-gated synNotch circuit (5.6 kb integration) at concentrations 5nM-160nM with corresponding knock-in efficiency, live cell count, and knock-in cell count 7 days post electroporation using Cas9 RNP or Cas9 mRNA. Each experiment was performed with T cells from two independent healthy human blood donors represented by individual dots plus mean. CTS, Cas9 target site. RNP, ribonucleoprotein. MOI, multiplicity of infection.

    Article Snippet: Knockout and knock-in efficiency were evaluated by staining for the TCR with an anti-TCRα/β antibody (Miltenyi Biotec) and staining for the CAR with recombinant BCMA protein (Biotinylated Human BCMA / TNFRSF17 Protein, His, Avitag, AcroBioSystems BCA-H82E4_200ug).

    Techniques: Knock-In, Electroporation, Comparison, Cell Characterization, Produced, Infection

    (a) Knock-in strategy and designs for BCMA-CAR (1.6 kb integration) at concentrations 5nM-160nM with corresponding (b) knock-in efficiency, (c) live cell count, and (d) knock-in cell count 7 days post electroporation for the following templates respectively: dsDNA, dsDNA + tCTS, ssDNA, ssDNA + tCTS, circular ssDNA + CTS, circular ssDNA + mutated v1 CTS v1, circular ssDNA + mutated v2 CTS. Circular cssDNA was produced and provided by Touchlight. (e) Knock-in strategy and designs for CAR-CARD-11 (3.5 kb integration) using linear ssDNA + tCTS template or a nanoplasmid + CTS template at concentrations 5nM-160nM with corresponding knock-in efficiency, live cell count, and knock-in cell count 7 days post electroporation.

    Journal: bioRxiv

    Article Title: Ultra-large targeted DNA integrations in primary human cells

    doi: 10.64898/2026.04.09.717505

    Figure Lengend Snippet: (a) Knock-in strategy and designs for BCMA-CAR (1.6 kb integration) at concentrations 5nM-160nM with corresponding (b) knock-in efficiency, (c) live cell count, and (d) knock-in cell count 7 days post electroporation for the following templates respectively: dsDNA, dsDNA + tCTS, ssDNA, ssDNA + tCTS, circular ssDNA + CTS, circular ssDNA + mutated v1 CTS v1, circular ssDNA + mutated v2 CTS. Circular cssDNA was produced and provided by Touchlight. (e) Knock-in strategy and designs for CAR-CARD-11 (3.5 kb integration) using linear ssDNA + tCTS template or a nanoplasmid + CTS template at concentrations 5nM-160nM with corresponding knock-in efficiency, live cell count, and knock-in cell count 7 days post electroporation.

    Article Snippet: Knockout and knock-in efficiency were evaluated by staining for the TCR with an anti-TCRα/β antibody (Miltenyi Biotec) and staining for the CAR with recombinant BCMA protein (Biotinylated Human BCMA / TNFRSF17 Protein, His, Avitag, AcroBioSystems BCA-H82E4_200ug).

    Techniques: Knock-In, Cell Characterization, Electroporation, Produced

    (a) Designs for BCMA-CAR (1.6 kb integration) HDRTs variants tested and corresponding template copies per genome measured at 4 hours and 3 days post electroporation (b) and half-life measured by qPCR. (c) Template copies per genome measured over time at 4 hours, 2 days, 3 days, 5 days, 7 days, and 12 days with R2 and half-life values corresponding to each donor. Each experiment was performed with T cells from two independent healthy human blood donors represented by individual dots plus mean. tCTS, truncated Cas9 target site. CTS, Cas9 target site. NP, nanoplasmid. cssDNA, circular cssDNA.

    Journal: bioRxiv

    Article Title: Ultra-large targeted DNA integrations in primary human cells

    doi: 10.64898/2026.04.09.717505

    Figure Lengend Snippet: (a) Designs for BCMA-CAR (1.6 kb integration) HDRTs variants tested and corresponding template copies per genome measured at 4 hours and 3 days post electroporation (b) and half-life measured by qPCR. (c) Template copies per genome measured over time at 4 hours, 2 days, 3 days, 5 days, 7 days, and 12 days with R2 and half-life values corresponding to each donor. Each experiment was performed with T cells from two independent healthy human blood donors represented by individual dots plus mean. tCTS, truncated Cas9 target site. CTS, Cas9 target site. NP, nanoplasmid. cssDNA, circular cssDNA.

    Article Snippet: Knockout and knock-in efficiency were evaluated by staining for the TCR with an anti-TCRα/β antibody (Miltenyi Biotec) and staining for the CAR with recombinant BCMA protein (Biotinylated Human BCMA / TNFRSF17 Protein, His, Avitag, AcroBioSystems BCA-H82E4_200ug).

    Techniques: Electroporation

    (a) Timeline of T cell knock-in electroporation workflow, knock-in strategy and designs for BCMA-CAR (1.6 kb integration) across the series of DNA HDR template formats tested. (b) Comparison of BCMA-CAR HDRTs at concentrations 5nM-160nM or 0-100E3 MOI in terms of knock-in efficiency, (c) live cell count per 1e6 edited cells, and (d) knock-in cell count per 1e6 edited cells measured 7 days post electroporation. (e) Knock-in of a logic-gated synNotch circuit (5.6 kb integration) using linear ssDNA + tCTS, circular cssDNA + CTS, and nanoplasmid + CTS templates with corresponding knock-in efficiency, live cell count and knock-in cell count 7 days post electroporation using Cas9 mRNA. Circular cssDNA was produced and provided by Kano Therapeutics. (f) Knock-in strategy and designs for a logic-gated synNotch circuit (5.6 kb integration) at concentrations 5nM-160nM with corresponding knock-in efficiency, live cell count, and knock-in cell count 7 days post electroporation using Cas9 RNP or Cas9 mRNA. Each experiment was performed with T cells from two independent healthy human blood donors represented by individual dots plus mean. CTS, Cas9 target site. RNP, ribonucleoprotein. MOI, multiplicity of infection.

    Journal: bioRxiv

    Article Title: Ultra-large targeted DNA integrations in primary human cells

    doi: 10.64898/2026.04.09.717505

    Figure Lengend Snippet: (a) Timeline of T cell knock-in electroporation workflow, knock-in strategy and designs for BCMA-CAR (1.6 kb integration) across the series of DNA HDR template formats tested. (b) Comparison of BCMA-CAR HDRTs at concentrations 5nM-160nM or 0-100E3 MOI in terms of knock-in efficiency, (c) live cell count per 1e6 edited cells, and (d) knock-in cell count per 1e6 edited cells measured 7 days post electroporation. (e) Knock-in of a logic-gated synNotch circuit (5.6 kb integration) using linear ssDNA + tCTS, circular cssDNA + CTS, and nanoplasmid + CTS templates with corresponding knock-in efficiency, live cell count and knock-in cell count 7 days post electroporation using Cas9 mRNA. Circular cssDNA was produced and provided by Kano Therapeutics. (f) Knock-in strategy and designs for a logic-gated synNotch circuit (5.6 kb integration) at concentrations 5nM-160nM with corresponding knock-in efficiency, live cell count, and knock-in cell count 7 days post electroporation using Cas9 RNP or Cas9 mRNA. Each experiment was performed with T cells from two independent healthy human blood donors represented by individual dots plus mean. CTS, Cas9 target site. RNP, ribonucleoprotein. MOI, multiplicity of infection.

    Article Snippet: To stain for BCMA-CAR, cells were incubated with 0.3 μg BCMA recombinant protein conjugated to biotin (Biotinylated Human BCMA / TNFRSF17 Protein, His, Avitag, AcroBioSystems, BCA-H82E4_200ug) for 15 minutes at room temperature prior to surface cell staining.

    Techniques: Knock-In, Electroporation, Comparison, Cell Characterization, Produced, Infection

    (a) Knock-in strategy and designs for BCMA-CAR (1.6 kb integration) at concentrations 5nM-160nM with corresponding (b) knock-in efficiency, (c) live cell count, and (d) knock-in cell count 7 days post electroporation for the following templates respectively: dsDNA, dsDNA + tCTS, ssDNA, ssDNA + tCTS, circular ssDNA + CTS, circular ssDNA + mutated v1 CTS v1, circular ssDNA + mutated v2 CTS. Circular cssDNA was produced and provided by Touchlight. (e) Knock-in strategy and designs for CAR-CARD-11 (3.5 kb integration) using linear ssDNA + tCTS template or a nanoplasmid + CTS template at concentrations 5nM-160nM with corresponding knock-in efficiency, live cell count, and knock-in cell count 7 days post electroporation.

    Journal: bioRxiv

    Article Title: Ultra-large targeted DNA integrations in primary human cells

    doi: 10.64898/2026.04.09.717505

    Figure Lengend Snippet: (a) Knock-in strategy and designs for BCMA-CAR (1.6 kb integration) at concentrations 5nM-160nM with corresponding (b) knock-in efficiency, (c) live cell count, and (d) knock-in cell count 7 days post electroporation for the following templates respectively: dsDNA, dsDNA + tCTS, ssDNA, ssDNA + tCTS, circular ssDNA + CTS, circular ssDNA + mutated v1 CTS v1, circular ssDNA + mutated v2 CTS. Circular cssDNA was produced and provided by Touchlight. (e) Knock-in strategy and designs for CAR-CARD-11 (3.5 kb integration) using linear ssDNA + tCTS template or a nanoplasmid + CTS template at concentrations 5nM-160nM with corresponding knock-in efficiency, live cell count, and knock-in cell count 7 days post electroporation.

    Article Snippet: To stain for BCMA-CAR, cells were incubated with 0.3 μg BCMA recombinant protein conjugated to biotin (Biotinylated Human BCMA / TNFRSF17 Protein, His, Avitag, AcroBioSystems, BCA-H82E4_200ug) for 15 minutes at room temperature prior to surface cell staining.

    Techniques: Knock-In, Cell Characterization, Electroporation, Produced

    (a) Designs for BCMA-CAR (1.6 kb integration) HDRTs variants tested and corresponding template copies per genome measured at 4 hours and 3 days post electroporation (b) and half-life measured by qPCR. (c) Template copies per genome measured over time at 4 hours, 2 days, 3 days, 5 days, 7 days, and 12 days with R2 and half-life values corresponding to each donor. Each experiment was performed with T cells from two independent healthy human blood donors represented by individual dots plus mean. tCTS, truncated Cas9 target site. CTS, Cas9 target site. NP, nanoplasmid. cssDNA, circular cssDNA.

    Journal: bioRxiv

    Article Title: Ultra-large targeted DNA integrations in primary human cells

    doi: 10.64898/2026.04.09.717505

    Figure Lengend Snippet: (a) Designs for BCMA-CAR (1.6 kb integration) HDRTs variants tested and corresponding template copies per genome measured at 4 hours and 3 days post electroporation (b) and half-life measured by qPCR. (c) Template copies per genome measured over time at 4 hours, 2 days, 3 days, 5 days, 7 days, and 12 days with R2 and half-life values corresponding to each donor. Each experiment was performed with T cells from two independent healthy human blood donors represented by individual dots plus mean. tCTS, truncated Cas9 target site. CTS, Cas9 target site. NP, nanoplasmid. cssDNA, circular cssDNA.

    Article Snippet: To stain for BCMA-CAR, cells were incubated with 0.3 μg BCMA recombinant protein conjugated to biotin (Biotinylated Human BCMA / TNFRSF17 Protein, His, Avitag, AcroBioSystems, BCA-H82E4_200ug) for 15 minutes at room temperature prior to surface cell staining.

    Techniques: Electroporation